Millendo Therapeutics, Inc.
MLND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $4 | $8 | $16 |
| G&A Expenses | $3 | $4 | $3 | $0 |
| SG&A Expenses | $3 | $4 | $3 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $8 | $11 | $16 |
| Operating Income | -$4 | -$8 | -$11 | $26 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | -$42 |
| Pre-Tax Income | -$4 | -$8 | -$11 | -$16 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$4 | -$8 | -$11 | -$16 |
| % Margin | – | – | – | – |
| EPS | -0.79 | -2.07 | -3.16 | 19.11 |
| % Growth | 61.8% | 34.5% | -116.5% | – |
| EPS Diluted | -0.79 | -2.07 | -3.16 | 19.11 |
| Weighted Avg Shares Out | 4 | 4 | 3 | 28 |
| Weighted Avg Shares Out Dil | 4 | 4 | 3 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | -$1 |
| EBITDA | -$3 | -$8 | -$11 | -$18 |
| % Margin | – | – | – | – |